CD274 and cancer: Though the introduction of ICB therapies (e.g., anti PD-1/PD-L1 agent) to oncology can transform the management of various malignancies, including HNSCC, the application of anti PD-1/PD-L1 agent alone cannot achieve favorable survival rate of patients with targeted cancer (2).